{
    "nct_id": "NCT00689559",
    "title": "A Single-Centre, Double-Blind, Randomised, Parallel Group Study of Repeated Oral Doses of AZD3480/Placebo and a Single Dose of Aripiprazole to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Aripiprazole in Healthy Subjects (Phase I)",
    "status": "COMPLETED",
    "last_update_time": "2009-06-30",
    "description_brief": "The purpose of the study is to evaluate if AZD3480 and warfarin interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "BASIC_SCIENCE",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "AZD3480 (selective \u03b14\u03b22 neuronal nicotinic acetylcholine receptor agonist)",
        "Aripiprazole",
        "Warfarin"
    ],
    "placebo": [
        "Placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests AZD3480, which is a nicotinic receptor agonist developed to improve cognitive function (attention/memory), not a biologic targeting Alzheimer's pathology (amyloid/tau). \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Act: Key details from the protocol and literature \u2014 AZD3480 has been investigated for cognitive improvement in Alzheimer's disease and other cognitive disorders and is described as a selective agonist of central \u03b14\u03b22 (and \u03b12\u03b22) neuronal nicotinic receptors. The specific trial cited (drug interaction with aripiprazole) is a Phase I PK interaction study (NCT00689559) and related interaction studies include warfarin (NCT00689637). These sources indicate the intervention is intended as a cognitive enhancer rather than a disease-modifying agent. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search6\ue201",
        "Reflect: Classification check \u2014 by the provided category definitions, AZD3480 is not a biologic (monoclonal antibody/vaccine) nor described as targeting core AD pathology (amyloid or tau). It is a small-molecule nicotinic agonist whose therapeutic rationale is to enhance cognition/attention. Therefore the correct category is 'cognitive enhancer'. Supporting trial records and publications confirm its cognitive/attention focus and the existence of multiple interaction/efficacy trials. \ue200cite\ue202turn0search7\ue202turn0search3\ue201",
        "Web search results (sources used): PubMed phase IIb study describing AZD3480 as a selective \u03b14\u03b22/\u03b12\u03b22 nicotinic agonist and cognitive investigations. \ue200cite\ue202turn0search0\ue201; Clinical trial registry entry for the AZD3480\u2013aripiprazole PK interaction (NCT00689559). \ue200cite\ue202turn0search1\ue202turn0search9\ue201; Clinical trial / CTV entry for AZD3480\u2013warfarin interaction (NCT00689637). \ue200cite\ue202turn0search6\ue201; Preclinical study showing AZD3480 reverses attentional impairment in rats. \ue200cite\ue202turn0search3\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The investigational drug AZD3480 (also called TC-1734) is a small-molecule agonist of central neuronal nicotinic acetylcholine receptors (selective for \u03b14\u03b22 and \u03b12\u03b22 subtypes) intended as a cognitive enhancer (improving attention/memory), not a disease-modifying biologic targeting amyloid or tau. \ue200cite\ue202turn0search0\ue202turn0search6\ue201",
        "Act: Extracted details \u2014 AZD3480/TC-1734 is described in clinical and preclinical reports as a selective \u03b14\u03b22 (and \u03b12\u03b22) nicotinic receptor agonist; the cited trial is a Phase I pharmacokinetic interaction study of AZD3480 with aripiprazole (NCT00689559) and there is a separate AZD3480\u2013warfarin interaction study (NCT00689637). The intervention therefore targets neurotransmitter receptors (nicotinic acetylcholine receptors). \ue200cite\ue202turn0search6\ue202turn0search3\ue202turn0search5\ue201",
        "Reflect: The CADRO category that best matches a drug acting as a nicotinic acetylcholine receptor agonist (a neurotransmitter receptor) is D) Neurotransmitter Receptors. Alternative nearby categories (for example synaptic plasticity/neuroprotection) are less specific than the explicit receptor-directed mechanism here. No evidence in the description indicates primary action on amyloid, tau, inflammation, or other CADRO categories, and the co-administered drugs (aripiprazole, warfarin) are included for PK interaction testing rather than as primary targets. \ue200cite\ue202turn0search3\ue202turn0search8\ue201",
        "Web search results (sources used):",
        "- PubMed: early human studies showing AZD3480 (TC-1734) is a selective \u03b14\u03b22 neuronal nicotinic receptor agonist with cognitive effects. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "- PubMed: Phase IIb study of AZD3480 in mild-to-moderate Alzheimer\u2019s disease describing receptor selectivity and cognitive endpoints. \ue200cite\ue202turn0search6\ue201",
        "- Clinical trial record (NCT00689559): AZD3480 \u2014 aripiprazole PK interaction study (Phase I). \ue200cite\ue202turn0search3\ue201",
        "- Clinical trial / registry entries for AZD3480 \u2014 warfarin interaction (NCT00689637) and related trial listings. \ue200cite\ue202turn0search5\ue202turn0search8\ue201"
    ]
}